<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"><channel><title>F.D.A. Rejects Closely Watched Lung Cancer Drug From China — Live Feed</title><link>https://www.live-feeds.com/feed/f-d-a-rejects-closely-watched-lung-cancer-drug-from-china</link><atom:link xmlns:atom="http://www.w3.org/2005/Atom" href="https://www.live-feeds.com/feed/f-d-a-rejects-closely-watched-lung-cancer-drug-from-china/rss.xml" rel="self" type="application/rss+xml"/><description>Continuously updated, source-cited coverage.</description>
<item><title>FDA rejects Summit's ivonescimab for EGFR-mutant lung cancer</title><link>https://www.live-feeds.com/feed/f-d-a-rejects-closely-watched-lung-cancer-drug-from-china</link><guid isPermaLink="false">https://www.live-feeds.com/feed/f-d-a-rejects-closely-watched-lung-cancer-drug-from-china#u209889</guid><pubDate>Fri, 20 Nov 2026 06:21:21 +0000</pubDate><description>The U.S. Food and Drug Administration declined to approve ivonescimab, a bispecific antibody targeting PD-1 and VEGF developed by Akeso and licensed by Summit Therapeutics, for previously treated EGFR-mutated non-small cell lung cancer. The rejection follows the HARMONI-2 trial&amp;#039;s failure to meet its primary overall survival endpoint despite showing progression-free survival benefit. Summit shares fell sharply on the news. The decision halts the first U.S. approval attempt for a PD-1/VEGF bispecific and leaves the drug&amp;#039;s U.S. path uncertain.Why it mattersIvonescimab was closely watche</description></item>
</channel></rss>